Lytix Biopharma is a clinical stage pharmaceutical company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer.

The Company’s technology is based on chemically optimized molecules generated from ”host defense peptides” – the nature’s first line of defense towards foreign pathogens. Lytix’ product candidate LTX-315 is a first-in-class* oncolytic peptide with the potential to fully personalize immunotherapy.

 

* ’’First-in-class’’ refers to a pharmaceutical which often has a new mechanism of action which differs from existing therapies, FDA Novel Drugs Summary, 2016.